Status:
COMPLETED
Phase 3 Study of MAP0004 in Adult Migraineurs
Lead Sponsor:
Allergan
Collaborating Sponsors:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Conditions:
Migraine Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This is a randomized, double blind, placebo controlled, parallel group study of MAP0004 in adult migraineurs. Subjects will self administer study drug in the outpatient setting.
Eligibility Criteria
Inclusion
- Major
- Male or female between 18 and 65 years of age.
- History of episodic, acute migraine (with or without aura) with onset prior to 50
- Major
Exclusion
- Known allergy or sensitivity or contraindication to study drugs or their formulations
- History of chronic pulmonary disease, coronary artery disease (CAD), liver disease, kidney disease, seizures, stroke, or major psychiatric condition.
- Any condition that, in the opinion of the Investigator, would make the subject unsuitable for study participation
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
902 Patients enrolled
Trial Details
Trial ID
NCT00623636
Start Date
July 1 2008
End Date
January 1 2011
Last Update
January 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Swedish Pain and Headache Clinic
Seattle, Washington, United States, 98104